Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY ) announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...
The following slide deck was published by Genmab A/S ADR in conjunction with this Read more ...
The following slide deck was published by Genmab A/S in conjunction with their 2018 Q1 earnings Read more ...
Genmab A/S (GNMSF) Q1 2018 Earnings Conference Call May 8, 2018 12:00 PM ET Executives Jan van de Winkel – President and Chief Executive Officer David Eatwell – Chief Financial Operator Analysts Michael Novod – Nordea James Quigley – JPMorgan W...
Genmab ( OTCPK:GNMSF ): Q1 EPS of DKK3.20 Revenue of DKK681M (+171.6% Y/Y) Press Release More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news,
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
Company Recap Cambridge, MA-based Unum Therapeutics ( UNUM ) was founded in 2014. The company has developed an antibody-coupled T-cell receptor [ACTR] platform that causes an individual’s cytotoxic T-lymphocytes [CTLs] to kill tumor cells when combined with tumor-specific antibodies...
Genmab A/S (GNMSF) Q4 2017 Results Earnings Conference Call February 21, 2018 12:00 a.m. ET Executives Jan van de Winkel - President and Chief Executive Officer David Eatwell - Chief Financial Officer Analysts Thomas Bowers - Danske Bank Sachin Jain - Bank of America Mich...
The following slide deck was published by Genmab A/S in conjunction with their 2017 Q4 earnings Read more ...
Genmab ( OTCPK:GNMSF ): FY Operating income of DKK1.34B. More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...